lol of course

ZVSA: effective April 26,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Closed the .80 gap buying back into ZVSA on weakness.

https://stockcharts.com/h-sc/ui?s=zvsa&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/zvsa/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/zvsa/opinion

https://finance.yahoo.com/quote/ZVSA/key-statistics

Open gap at .80

Goodmorning


https://stocktwits.com/3227blake/message/563183532

$$$ZVSA$$$

ZVSA: Un-plugged it from halt!!!

ZVSA: Just a science "WHITE PAPER" does this??? And from DAYS AGO???

ZVSA: Let's get ready to RUMMMMMMMMMM-BULL!!!!!

RUNNER ON MONDAY

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

ZVSA..................................https://stockcharts.com/h-sc/ui?s=ZVSA&p=W&b=5&g=0&id=p86431144783

#ZVSA 🔥 big move next week? Low float, huge upside? $ZVSA

Started move around 3 30

Strong in a h
Set up to run Monday.

$$$$ ??? $$$

ZVSA new 52 week low

$ZVSA$ Nice move today...

Bought in at 0.925 ish

GhosT

ZVSA READY TO BREAK A NEW HIGH

LOW VOLUME COMBUSTION

ZVSA...ON THE MOVE POST SPLIT

ZVSA new 52 week low

ZVSA new 52 week low

$ZVSA NEWS , POST 1-35 RS DEC 4

https://finviz.com/quote.ashx?t=ZVSA&ty=c&ta=1&p=d

NOV S-1 IN PROGESS
https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92612528/form-424b3-prospectus-rule-424b3
https://dilutiontracker.com/app/search/ZVSA

ZVSA Boomtime up 72% quickly .11

ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and progressive bowel damage.
Study provides direct evidence that NLRP3 signaling is over-activated in IBD, and that its inhibition attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
WESTON, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.

In the paper titled, “Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation,” the authors evaluated human colon biopsy samples from patients with IBD and healthy controls, and conducted a study in an IBD mouse model. Following are key findings reported in the paper:

NLRP3 and IL-1ß expression is increased in the colon of IBD patients.
NLRP3 inhibition in the IBD animal model: Inhibited NLRP3 inflammasome signaling in the colon, resulting in significantly reduced levels of the pro-inflammatory cytokines IL-1b, IL-6, and TNF-a.Alleviated severe diarrhea and significantly improved IBD symptoms, based on the disease activity index score.Attenuated histopathological changes indicative of tissue damage (goblet cell reduction, crypt destruction, and epithelial barrier disruption).Restored gut microbiota to normal.
The authors stated, “In conclusion, this study provides direct evidence that NLRP3 signaling is over-activated in IBD patients. The inhibition of NLRP3 reverses the IBD-like symptoms in DSS-induced mice, which the regulatory effects on gut microbiota might mediate. Overall, this present study provides a basis for the clinical application of NLRP3 as a target for IBD treatment.” To read the article, Click Here.

“Restoration of quality of life is the ultimate long-term goal in IBD management. Although disease remission can often be achieved with current therapies, bothersome symptoms can still prevail,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “The research published in the Biomedical Journal provides support for inflammasome inhibition as a promising treatment option for IBD. ZyVersa is developing Inflammasome ASC inhibitor IC 100. Unlike NLRP3 inhibitors, designed to inhibit formation of one inflammasome to block initiation of the inflammatory cascade, IC 100 was designed to inhibit multiple types of inflammasomes and their associated ASC specks to uniquely block both initiation and perpetuation of damaging inflammation, which we believe is necessary to control chronic inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About Inflammasome ASC Inhibitor IC 100

IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1ß early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1ß and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product

ZVSA pump failed for the buyers.

fake traders never get it right

Here comes the momo

Zvsa 😀

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuro

Keep buying. The losers of the biopharma pump and dump are loving your buys.

me 2

Yeah I made the mistake of buying into this one on the pump over the summer that was going on. It has crashed ever since.

Most Micro stocks are and act like garbage 80% of the time, there only swing trades or day trades, unless there is some really big news that can get them, and can keep them out of the sewer, where most of them end up swimming, they are always stock offering risks,especially after quick run ups, I own it in the low $0.12, it's been getting a good amount of buyside volume in the past few days, and could be setting up for more gains.

don't play options, but this stock is garbage...

You are not even worth answering back to, other then for the entertainment value of it, you are such a clueless fool with your comments more than 95% of the time, then again,you have allready proved that on other boards, go buy some more $SPY calls, bet that's been going real well, that is if you like accumulating red bags.

now we know you have no clue what you are doing

It needs to break back above $0.14 again today,and close above that level, and get the manipulators that keep show size on the offer off its back,if the market wasn't down again today it could of possible took out $0.15, it could be setting up for a run to $0.18 in the short term, especially if the fools on the offer get taken out.

Yup, the 63 split window is one of the favorite and nicest looking C2 vetts, I always liked the 67 big block, mine is a 350,350 small block yellow convertible, I have had it since 1981, I am the second owner since then.

Zvsa is a muscle car racing up today

Gotta love the classic muscle of vettes,69 is a popular year for all muscle cars,hang on to that one,my fav is 63 split window

Going by your name,I'm guessing you own an 81 corvette,I own a 69 vette.

Definitely a brainless moron who keeps showing size on the offer, could be a real dumbass short position,trying to stop a breakout so they get squeezed,and their butts handed to them.

51% win 2 Wednesdays ago,let’s see what this one does

The D bag is now showing size at $0.1545, the creeps need to get squeezed and have to cover over $0.16.

Douche bag manipulator showing zize at $0.15, probably because they haven't covered their short yet, time to squeeze the corrupt SOB.

Implode is more like it

This can explode at any moment!

I don't like fleas! SMH.
Thnx for posting this.

Oye Vay. :(

ANOTHER DOG WITH FLEAS https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92040892/form-8-k-current-report

ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

September 12 2023

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a paper in the peer-reviewed journal, Frontiers in Immunology, highlighting potential limitations of NLRP3 inhibition in attenuating CNS Inflammation associated with activation of multiple inflammasome pathways. This paper supports ZyVersa’s rationale for targeting inflammasome ASC with IC 100 to inhibit multiple inflammasome pathways, not just NLRP3, to control inflammation in various inflammatory diseases.

In the paper titled, “Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALS,” the authors conducted studies in various human cell lines and in an animal model of ALS. Data demonstrate that NLRP3 inhibition alone is insufficient to attenuate proinflammatory cytokine release and inflammatory cell death associated with activation of multiple inflammasome pathways. Likewise, NLRP3 inhibition alone did not ameliorate spinal cord inflammation in an ALS model.

The authors stated, “we hypothesize that strategies that impact multiple inflammasome pathways may hold more promise in CNS disorders like ALS where multiple inflammasomes are dysregulated.” To read the article Click Here.

“The research published in Frontiers in Immunology reinforces the need to inhibit more than the NLRP3 inflammasome pathway to control inflammation associated with activation of multiple inflammasomes,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “ZyVersa’s Inflammasome ASC inhibitor IC 100 is designed to inhibit formation of multiple types of inflammasomes to attenuate initiation of the inflammatory cascade, and to inhibit ASC specks to attenuate perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1ß early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1ß and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92019000/zyversa-therapeutics-announces-research-published

$ZVSA